Indiana University School of Medicine, Indianapolis, 6 Indiana University School of Medicine, Indianapolis, IN, 7 RI 2606, Indiana University, Indianapolis, IN. RATIONALE: Insurance companies frequently change the preferred inhaled corticosteroid (ICS) for asthma. This causes gaps in medication utilization as pharmacies, physicians, and patients work to comply with the change. To determine if these changes impacted children with severepersistent asthma, we performed a two year retrospective chart review (2016) (2017) of hospitalization and emergency department (ED) visits. METHODS: Hospitalization and ED visits of 98 children (median age 10 years) in our high-risk asthma clinic were reviewed between January 2016 to December 2017. Medication refill history, changes in insurance, and reasons for ED visits/hospitalizations were reviewed. Patients with <2 refills of ICS within 3 months and physician documentation of not taking medication despite continuous ICS access, were labeled ''non-compliant.'' Patients encountering changes in preferred ICS were labeled as ''medication refill issue.'' Data were analyzed using Wilcoxon non-parametric test. RESULTS: In our high-risk asthma patients, a change in preferred ICS was associated with increased rates of ED visits (p50.002) and hospitalizations (p5.009). When examining the reason for the ED visit or hospitalization, we found that ''non-compliant'' patients had more ED visits than patients who were always compliant with medication (p50.002), but they did not have higher hospitalization rates (p50.37). Furthermore, ''medication refill issues'' led to increased ED visits (p<0.001) and hospitalizations (p50.012). CONCLUSIONS: High-risk asthma patients have a higher likelihood of ED visits and hospitalizations when their ICS changes. Working to keep their preferred ICS consistent is crucial in reducing health care costs. Further investigation is needed to determine if non-compliance may be linked with frequent ICS changes. Indeed, animal studies have demonstrated that testosterone inhibits airway smooth muscle proliferation and bronchospasm. We therefore investigated whether serum testosterone inversely correlates with current asthma prevalence using cross-sectional data from the 2011-2012 National Health and Nutrition Examination Survey (NHANES) database. METHODS: Serum testosterone and current asthma history were obtained from n57,584 patients ages 1-80 years, n5601 with current asthma. Logistic regression was used to determine associations between serum testosterone and current asthma, adjusting for demographic variables and stratifying for gender and age. RESULTS: Each 25ng/dL serum testosterone increase in the general study population resulted in a 3% decrease in the odds of current asthma (95%CI 1-4%, p50.002). When the range of serum testosterone was divided into tertiles, the highest tertile was associated with a 58% decrease in the odds of current asthma relative to the lowest tertile (n51,904, 95%CI 29-75%, p50.003). In continuous data, this trend was present regardless of gender, and more prominent in females: males (3% decrease, 95%CI 1-7%, p50.044), females (31% decrease, 95%CI 11-46%, p50.006). For patients older than or equal to 12 years, the highest serum testosterone tertile was associated with a 47% decrease in the odds of current asthma relative to the lowest tertile (n54, 930, p<0.001) . No association was seen in patients younger than 12 years (n5782). CONCLUSIONS: Data from NHANES demonstrate an inverse relationship between serum testosterone and current asthma prevalence suggesting a possible protective effect of testosterone on asthma development.
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Prenatal exposure to acid suppressant medications and the risk of recurrent wheeze at 3 years of age in children with a history of severe bronchiolitis Brigham and Women's Hospital, Boston, MA. RATIONALE: Infants diagnosed with severe bronchiolitis are at higher risk for developing recurrent wheeze and asthma. Prior studies from outside the United States (U.S.) suggest that prenatal exposure to acid suppressant medications (ASM), such as proton pump inhibitors and histamine-2 receptor antagonists, may increase the risk of developing asthma. We tested the hypothesis that prenatal exposure to ASM increases the risk of recurrent wheeze among a high-risk population of children with a history of severe bronchiolitis. METHODS: We enrolled 921 infants hospitalized for bronchiolitis from 2011-2014 in a multi-center, U.S.-based prospective cohort. ASM use during pregnancy was ascertained by parent report. Children were followed for the development of recurrent wheeze by age 3 years (defined by 2007 NIH guidelines). Time-to-event analysis was performed using multivariable Cox-proportional hazards models stratified by age and adjusted for sex, race/ethnicity, income, maternal history of atopy, maternal smoking during pregnancy, use of antibiotics during pregnancy, gestational age at birth, multiple gestation and mode of delivery. RESULTS: Of the 921 infants enrolled in the longitudinal cohort, 900 children with complete data were included in this analysis. Prenatal exposure to ASM occurred in 16% (144/900) of children. Recurrent wheeze developed in 31% (233/756) of unexposed children as compared to 39% (56/144) of exposed children (unadjusted HR 1.38;95%CI, 1.03-1.85). The finding did not change after adjustment (adjusted HR 1.40;95% CI, 1.02 -1.91). CONCLUSIONS: In this high-risk cohort of U.S. children with a history of severe bronchiolitis, prenatal exposure to ASM further increased the risk of developing recurrent wheeze by 3 years of age.
